Inventera: 투자판단관련주요경영사항(임상시험계획승인신청) (자기공명 췌담관조영술(MRCP) 특화 조영제 INV-003액의 미국 FDA 제1상 임상시험계획(IND) 신청)

Filed Investigational New Drug (IND) application with US FDA for Phase 1 trial of contrast agent INV-003

Key figures: 임상시험기간 약 12개월·대상자 최대 30명

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

• 09.21 ★★★★ Received final clinical study report for Phase 3 trial of contrast agent INV-002